Company intelligence / Profile preview

Tanai Therapeutics

Ghent (Afsnee), Belgiumvib.be ↗

Ownership: Private
Development stage: Preclinical

Overview

Developing a first-in-class oral therapeutic targeting a novel, genetically validated pathway in obesity. The approach aims to selectively promote fat loss while preserving muscle mass, offering a different mechanism than current obesity treatments that focus on appetite suppression.

Therapeutic areas: Metabolic DisordersEndocrinology
Modalities: Small molecules (oral therapeutic)
Industry: Biotech

Drug pipeline

1 asset

Undisclosed

Pre-clinical

Indications: Obesity

Partnerships

Novo Nordisk A/S

Beyond the preview

Go deeper on Tanai Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tanai Therapeutics.

Explore the full profile